Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, Giuliana Cologni et al.|Digestive and Liver Disease|2014Cited by 23
Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohortAlessandro Soria, G. Aimo, Marco Fava et al.|Liver International|2020Cited by 19
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort StudyLuca Valenti, Serena Pelusi, Alessio Aghemo et al.|Hepatology Communications|2021Cited by 14
Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral HepatitisAlessio Aghemo, M. Colombo, Giuliana Cologni et al.|Journal of Hepatology|2016Cited by 8
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from ItalyL. Pasulo, Giuliana Cologni, M. Gambato et al.|Digestive and Liver Disease|2019Cited by 1